Segulah Medical Acceleration (SMA), Copenhagen

https://www.segulahmedical.com

Segulah Medical Acceleration (“SMA”) is a Scandinavia-based investment company focusing on innovative medical technology companies with global potential. SMA’s objective is to be an active partner and help its portfolio companies accelerate growth and internationalization and reach commercial proof of concept. SMA’s geographic investment remit is focused on Scandinavia and other Western European countries. The areas within Medtech that SMA prioritizes include medical devices and consumables, diagnostics, life science tools, and digital technologies. SMA has more than SEK 1.25 billion (€ 125m equivalent) in investable funds. *

	Start	2022-07-12 existent
	Group	Segulah Medical Acceleration (SMA)
	Today	Segulah Medical Acceleration (SMA)
	Industry	investment management
	Industry 2	MedTech (medical technology)

	Region	København (Copenhagen)
	Country	Denmark
	City	n. a.
		Address record changed: 2022-07-18

Basic data	Employees	n. a.

		* Document for »About Section«: Navinci Diagnostics AB. (7/12/22). "Press Release: Navinci Diagnostics AB Announces Closing of SEK 90M Series A Financing, Led by Segulah Medical Acceleration with Support from Existing Shareholders".

		Record changed: 2024-02-12

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Segulah Medical Acceleration (SMA)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)